Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
| Revenue (Most Recent Fiscal Year) | $9.94M |
| Net Income (Most Recent Fiscal Year) | $-164.57M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 13.83 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.50 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1656.34% |
| Net Margin (Trailing 12 Months) | -1656.34% |
| Return on Equity (Trailing 12 Months) | -227.91% |
| Return on Assets (Trailing 12 Months) | -75.60% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.95 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.95 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 2.07 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.79 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.19 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.70 |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.76 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 26.73M |
| Free Float | 23.93M |
| Market Capitalization | $137.38M |
| Average Volume (Last 20 Days) | 0.28M |
| Beta (Past 60 Months) | 1.74 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.45% |
| Percentage Held By Institutions (Latest 13F Reports) | 91.47% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |